The stock's rise snapped a three-day losing streak.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $197.43, a high estimate of $246.00, and a low estimate of $143.00. Surpassing the previous average price ...

Headquartered in Cambridge, Massachusetts, Biogen Inc. (BIIB) researches, develops, and commercializes therapies for severe ...

Is Biogen (NASDAQ: BIIB) about to be acquired? One news article published on Wednesday reported that this is a possibility. As a result, the company's shares shot up almost 10% higher on the day. It ...

Shares of Biogen Inc. BIIB slid 1.06% to $192.08 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.28% to 6,861.89 and Dow ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

The biotech published its last set of financials for 2025. Its quarterly revenue and adjusted profitability declined, yet both still topped the consensus analyst estimates. One of the healthier stocks ...

Biogen recently reported fourth-quarter and full-year 2025 results showing quarterly sales of US$521.2 million and revenue of US$2.28 billion, but a quarterly net loss of US$48.9 million contrasted ...

Biogen Inc.'s earnings and share price have declined due to falling Multiple Sclerosis treatment revenue; new drugs and pipeline show promise but haven't offset losses yet. Biogen's Multiple Sclerosis ...